ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ALT Altimmune Inc

5.90
-0.01 (-0.17%)
Last Updated: 18:42:48
Delayed by 15 minutes
Share Name Share Symbol Market Type
Altimmune Inc NASDAQ:ALT NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.01 -0.17% 5.90 5.89 5.90 6.08 5.78 5.90 1,299,948 18:42:48

Altimmune to Participate at Two Upcoming Investor Conferences

07/05/2024 12:30pm

GlobeNewswire Inc.


Altimmune (NASDAQ:ALT)
Historical Stock Chart


From Apr 2024 to Jun 2024

Click Here for more Altimmune Charts.

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences:

  • JMP Life Sciences Conference (New York, NY)Tuesday, May 14, 2024Fireside Chat at 9:00 a.m. Eastern Time
  • UBS Obesity Therapeutics Day (Virtual Conference)Thursday, May 23, 2024Fireside Chat at 10:00 a.m. Eastern Time

The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter

Company Contact:Richard Eisenstadt                                                        Chief Financial Officer                                                 Phone: 240-654-1450                                                        ir@altimmune.com

Investor Contact:Lee RothBurns McClellanPhone: 646-382-3403lroth@burnsmc.com Julia WeilmanBurns McClellanPhone: 646-732-4443jweilman@burnsmc.com

Media Contact:Danielle CanteyInizio Evoke CommsPhone: 619-826-4657Danielle.cantey@inizioevoke.com 

1 Year Altimmune Chart

1 Year Altimmune Chart

1 Month Altimmune Chart

1 Month Altimmune Chart

Your Recent History

Delayed Upgrade Clock